Back to News
Market Impact: 0.3
Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
Source: Newswire
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Canada became the first country to authorize Moderna’s mRNA seasonal influenza vaccine, mFLUSIVA, and its combination influenza and COVID-19 vaccine, mCOFLU. The approvals are a positive regulatory milestone for the two products; the article provides no sales forecasts or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
MRNA0.80
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- South Korea’s KOSPI halts trade after 8% wipeout on AI losses
- U.S. stock futures rise after AI rout batters Wall St; payrolls data in focus
- ’Our phones are exploding’: Goldman Sachs dissects historic Wall Street crash
- e.l.f. CEO: All of Our Brands Are Growing